These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32976243)

  • 41. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
    Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
    Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coronary angioscopic findings 9 months after everolimus-eluting stent implantation compared with sirolimus-eluting stents.
    Dai K; Ishihara M; Inoue I; Kawagoe T; Shimatani Y; Miura F; Nakama Y; Otani T; Ooi K; Ikenaga H; Nakamura M; Miki T; Kishimoto S; Sumimoto Y
    J Cardiol; 2013 Jan; 61(1):22-30. PubMed ID: 23078862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
    Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
    JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early Vascular Healing Following Bioresorbable-Polymer Sirolimus-Eluting Stent Placement Compared to That with Durable-Polymer Everolimus-Eluting Stent.
    Ogura K; Tsujita H; Oishi Y; Matsumoto H; Matsukawa N; Sakai R; Arai T; Sato S; Tanaka H; Masaki R; Arai K; Nomura K; Kosaki R; Sakai K; Sekimoto T; Kondo S; Tsukamoto S; Mori H; Yamamoto MH; Wakabayashi K; Suzuki H; Ochiai M; Shinke T
    Int Heart J; 2021 May; 62(3):510-519. PubMed ID: 33994509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patients with acute myocardial infarction.
    Gąsior P; Gierlotka M; Szczurek-Katanski K; Osuch M; Roleder M; Hawranek M; Gasior M; Wojakowski W; Polonski L
    Postepy Kardiol Interwencyjnej; 2018; 14(4):347-355. PubMed ID: 30603024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial.
    Orvin K; Carrie D; Richardt G; Desmet W; Assali A; Werner G; Ikari Y; Fujii K; Goicolea J; Dangoisse V; Manari A; Saito S; Wijns W; Kornowski R
    Catheter Cardiovasc Interv; 2016 May; 87(6):1092-100. PubMed ID: 26268482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angioscopic assessment of arterial repair following biodegradable polymer-coated biolimus A9-eluting stent implantation. - Comparison with durable polymer-coated sirolimus-eluting stent-.
    Awata M; Uematsu M; Sera F; Ishihara T; Watanabe T; Fujita M; Onishi T; Iida O; Ishida Y; Nanto S; Nagata S
    Circ J; 2011; 75(5):1113-9. PubMed ID: 21389636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse cardiovascular events associated with biodegradable polymer drug-eluting stents and durable polymer everolimus-eluting stents: A systematic review and meta-analysis of 10 randomized controlled trials.
    Bundhun PK; Janoo G; Yanamala CM; Huang F
    Medicine (Baltimore); 2017 Jul; 96(28):e7510. PubMed ID: 28700502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of early-phase arterial repair following cobalt-chrome everolimus-eluting stent and slow-release zotarolimus-eluting stent: an angioscopic study.
    Ishihara T; Iida O; Fujita M; Masuda M; Okamoto S; Nanto K; Kanda T; Tsujimura T; Sunaga A; Awata M; Nanto S; Uematsu M
    Cardiovasc Interv Ther; 2018 Apr; 33(2):163-168. PubMed ID: 28255728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Khattab AA; Taniwaki M; Rigamonti F; Nietlispach F; Blöchlinger S; Wenaweser P; Jüni P; Windecker S
    EuroIntervention; 2016 Dec; 12(11):e1343-e1354. PubMed ID: 26690319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial.
    Wöhrle J; Markovic S; Rottbauer W; Muramatsu T; Kadota K; Vázquez-González N; Odenstedt J; Serra A; Antoniucci D; Varenne O; Saito S; Wijns W
    EuroIntervention; 2016 Jun; 12(2):e167-74. PubMed ID: 27290676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials.
    Vlachojannis GJ; Puricel S; Natsuaki M; Morimoto T; Smits PC; Kimura T
    EuroIntervention; 2017 Mar; 12(16):1970-1977. PubMed ID: 27802927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.
    Buszman PP; Michalak MJ; Pruski M; Fernandez C; Jelonek M; Janas A; Savard C; Gwiazdowska-Nowotka B; Żurakowski A; Wojakowski W; Buszman PE; Milewski K
    Cardiol J; 2016; 23(6):657-666. PubMed ID: 27976797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
    Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
    Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
    Iglesias JF; Heg D; Roffi M; Degrauwe S; Tüller D; Muller O; Brinkert M; Cook S; Weilenmann D; Kaiser C; Cuculi F; Valgimigli M; Jüni P; Windecker S; Pilgrim T
    Cardiovasc Revasc Med; 2022 Jan; 34():3-10. PubMed ID: 33653633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
    van Geuns RJ; Chun-Chin C; McEntegart MB; Merkulov E; Kretov E; Lesiak M; O'Kane P; Hanratty CG; Bressollette E; Silvestri M; Wlodarczak A; Barragan P; Anderson R; Protopopov A; Peace A; Menown I; Rocchiccioli P; Onuma Y; Oldroyd KG
    EuroIntervention; 2022 Apr; 17(18):1467-1476. PubMed ID: 35285803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison between biodegradable- and durable-polymer everolimus-eluting stents in hemodialysis patients with coronary artery disease.
    Ito R; Ishii H; Oshima S; Nakayama T; Sakakibara T; Kakuno M; Murohara T
    Cardiovasc Interv Ther; 2022 Jul; 37(3):475-482. PubMed ID: 34817827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of current smoking on 2-year clinical outcomes between durable-polymer-coated stents and biodegradable-polymer-coated stents in acute myocardial infarction after successful percutaneous coronary intervention: Data from the KAMIR.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    PLoS One; 2018; 13(10):e0205046. PubMed ID: 30289945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.